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RNAs encoding subunits of glutamate-gated ion chan-
nel receptors are posttranscriptionally modified by RNA
editing and alternative splicing. The change in amino
acid sequence caused by RNA editing can affect both the
kinetics and the permeability of the ion channel recep-
tors to cations. Here, we report the purification of a
90-kDa double-stranded RNA-specific adenosine deami-
nase from HeLa cell nuclear extract that specifically
edits the glutamine codon at position 586 in the
pre-mRNA of the glutamate receptor B subunit. Site-
specific deamination of an adenosine to an inosine con-
verts the glutamine codon to that of arginine. Recently,
a gene encoding a double-stranded-specific editase
(RED1) was cloned from a rat brain cDNA library. Anti-
bodies generated against the deaminase domain of its
human homolog specifically recognized and inhibited
the activity of the 90-kDa enzyme, indicating that we
have purified hRED1 the human homolog of rat RED1.
This enzyme is distinct from double-stranded RNA-spe-
cific adenosine deaminase which we and others have
previously purified and cloned.
RNA editing, defined as an alteration in the coding capacity
of mRNA other than splicing or 39-end processing, was first
observed in the kinetoplast of trypanosomes (1). Originally
thought to be a mechanism of generating genetic diversity only
in the mitochondria or chloroplasts of lower organisms and
plants, the discovery of editing of the apolipoprotein B (apoB)1
mRNA suggested that editing was also widespread in mam-
mals (2, 3). To date there are several examples of mammalian
RNA editing, the most dramatic perhaps being the editing of
the pre-mRNA of glutamate-gated ion channel receptor sub-
units in the brain (see Ref. 4 for review).
L-Glutamate is the major excitatory neurotransmitter in the
vertebrate central nervous system. The ionotropic glutamate
receptors (GluR) have been classified into three subtypes based
on their selectivity to agonists and antagonists; the a-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA),
N-methyl-D-aspartate (NMDA), and kainate receptors. The re-
ceptors are comprised of 17 sequence-related subunits (5–7). 5
out of the 17 are edited (see Refs. 8, 9 for reviews) and have a
conversion from adenosine in the genomic sequence to inosine
in the mRNA (10–12); inosine is read as if it were a guanosine
by the translational machinery (13). This generates a substi-
tution in an amino acid in the receptor subunit and can have
major consequences on the properties of the ion channel (see
Ref. 14 for review).
Arginine at position 586 of the GluR-B subunit controls the
low Ca21 permeability of the heteromeric AMPA receptors (15,
16). This arginine is generated by site-specific deamination of a
CAG glutamine codon (Q) to a CIG arginine codon (R) (10–12).
In the rat brain the Q/R site is edited at all developmental
stages. Interestingly, the only known example where this site is
not edited is in fish, where an arginine is already encoded in
the genomic sequence (17). The formation of an intramolecular
RNA duplex between portions of exon 11 and intron 11 of
GluR-B pre-mRNA is required for RNA editing (18). Transgenic
mice harboring a mutation on one of their alleles that disrupts
this base pairing capacity are unable to edit the Q/R site,
develop early onset epilepsy, and die within 3 weeks of birth
(19). It is thought that this may be the result of increased Ca21
influx, eventually leading to neuronal degeneration.
The dsRNA-specific adenosine deaminase (DRADA) is a
ubiquitous enzyme that has been purified (20–23) and cloned
from different sources (24–26). We investigated whether the
DRADA we had isolated from calf thymus could edit the
GluR-B pre-mRNA. We found that the purified enzyme was
unable to edit the Q/R site in the GluR-B pre-mRNA to signif-
icant levels in vitro (27) but edited the R/G and hotspot 1 sites
in addition to the Q/R site in the pre-mRNAs of the kainate
receptor subunits GluR-5 and GluR-6 (27, 28). A comparison of
the potential of these editing sites to form a double-stranded
RNA structure suggested that DRADA could edit an adenosine
if it was in a mismatched position, either a loop or a bulge,
whereas the adenosine at the Q/R site is in a perfect duplex.
These results suggested that the Q/R site in GluR-B pre-mRNA
was very different from the sites edited by DRADA and was
edited by a different activity (27).
Fractionation of HeLa cell nuclear extract separated an ac-
tivity from DRADA that could specifically edit the GluR-B Q/R
site (12, 27). One of the methods employed to separate these
two activities was gel filtration, the molecular weight of the
Q/R editing activity being lower than that of DRADA (27). It
had been postulated that a complex between DRADA and a
cofactor was responsible for Q/R editing (29–31), but we were
unable to find such a complex. During fractionation of HeLa
cell nuclear extract no fraction added to DRADA made it Q/R
editing-competent nor could polyclonal antibodies raised
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against the dsRNA binding domain (dsRBD) of DRADA recog-
nize the Q/R editing activity (27). Therefore, we concluded that
another enzyme was responsible for editing the Q/R site in the
GluR-B pre-mRNA.
The editing activity that specifically edits the GluR-B Q/R
site was purified from HeLa nuclear extracts by chromatogra-
phy over seven columns. A second dsRNA adenosine deami-
nase, dsRNA-specific editase 1 (RED1), that can specifically
edit the GluR-B Q/R and R/G sites has recently been cloned
from a rat brain cDNA library (32). This enzyme is 31% iden-
tical to DRADA and is comprised of two dsRBD and a deami-
nase domain (32). Polyclonal antibodies were generated
against its deaminase domain that recognized and inhibited
the deaminase activity of the purified 90-kDa enzyme but not
DRADA. We therefore conclude that we have purified human
dsRNA-specific editase 1 (hRED1).
EXPERIMENTAL PROCEDURES
GluR Constructs and Oligonucleotides—GluR-B minigenes used in
this study were B13 (encoding the Q/R- and hotspot 1-edited sites) (18)
and pBgl (encoding the R/G sites) (10); these constructs were linearized
and the RNA transcribed as described previously (10). The antisense
oligonucleotide used in the primer extension assay was B-RT; 59-GGC-
GAAATATCGCATCCTTG-39 which is complementary to the Q/R-edited
site (10); BHS-RT, 59-ACCATGAATATCCACTTGAG-39 is the antisense
primer used in the primer extension assay to measure editing at the
hotspot 1 in GluR-B intron 11. The primers for PCR, reverse transc-
ription, and sequencing were KMH3, 59-GACACGGTACCACACAACG-
GCATTTCCATGAATTGATGTTAGAG-39 which is a reverse tran-
scriptase primer antisense on minigene B13; BFFK3, 59-GACACGGT-
ACCACACAACGGATTGTGAGTTACCTCATATCCG-39 which is
another reverse transcriptase primer antisense on minigene pBgl;
PCRK3, 59-GACACGGTACCACACA ACGG-39, a PCR primer for cDNA
primed with KMH3 or BFFK3; cis55, 59-CTCTGCGAGCTCAGGTC-
CAACTGCACCTCGG-39 a vector specific 59-primer; MH50, 59-GAC-
CCTGTAGGAAAAATCTAACC-39, antisense on minigene B13; MH36,
59-TCACCAGGGAAACACATGATCAAC-39 antisense on minigene B13;
Bint1, 59-GCGGTACCGTGAGTTACCTCATA TCCGTAT-39 antisense
on minigene pBgl; (10) and Bint2, 59-ATCTCTAGACAAACCGTTAA-
GAGTC-39, which is also antisense on minigene pBgl (27). The PCR
primers used for cloning ESTs homologous to RED1 were R1, 59-CTA-
CAGGATCCAAATGTATTAATGG-39; and R2, 59-CCACCGTGCA
AGCTTGTCACTGC-39.
Purification of hRED1—The principal buffer used in this purification
was buffer A (50 mM Tris-HCl, pH 7.9, 5 mM EDTA, 10% glycerol, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 0.7 mg/ml pepsta-
tin, and 0.4 mg/ml leupeptin). Most of the columns were developed with
a KCl gradient so therefore the KCl concentration used is indicated
below. All manipulations were carried out at 4 °C; fractions were frozen
in liquid nitrogen and stored at 270 °C. Aliquots of column fractions
were dialyzed against buffer A containing 200 mM KCl for 2 h before
being assayed both for their ability to edit the Q/R and hotspot 1 sites
of GluR-B by primer extension assay (10) and for deaminase activity
(22). HeLa cell nuclear extract (14.67 g of protein which is the equiva-
lent of approximately 1,500 liters of HeLa cells) was prepared by stand-
ard method (33). The nuclear extract was divided in two and loaded
separately onto a 1.6-liter Macro-Prep High Q column (Bio-Rad), which
had been equilibrated with buffer A containing 50 mM KCl. The column
was washed with 1 column volume and developed with an 8-liter gra-
dient from 50 to 500 mM KCl. The Q/R editing activity eluted with a
broad peak from 130 to 280 mM KCl. The active pools from both Macro-
Prep High Q columns were combined, the conductivity was adjusted to
300 mM KCl, the pool was then divided in two and loaded separately on
a 300-ml Affi-Gel blue column (Bio-Rad). The column was washed with
2 column volumes of buffer A containing 300 mM KCl and developed
with a 5-column KCl gradient 300-1000 mM KCl. The Q/R editing
activity eluted between 480 and 800 mM KCl; the pools from both
Affi-Gel blue columns were again combined; 10 mM CaCl2 was added to
the active pool, and it was loaded directly onto a 350-ml Ultrogel
hydroxyapatite column (IBF Biotechnics). The hydroxyapatite column
had been equilibrated with buffer B (20 mM Tris-HCl, pH 7.9, 50 mM
KCl, 10% glycerol, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 0.7 mg/ml pepstatin, and 0.4 mg/ml leupeptin). The column was
washed with 2 column volumes and developed with an 8-column gradi-
ent of 0–500 mM potassium phosphate, pH 7.9, in buffer B. The Q/R
editing activity eluted between 90 and 160 mM potassium phosphate.
After extensive dialysis against buffer C (same as buffer A except for 50
mM HEPES-KOH, pH 7.9 replacing Tris-HCl) containing 50 mM KCl,
the active pool was loaded onto an 8-ml Mono S column which had been
equilibrated with buffer C. The column was washed with 3 column
volumes, and the editing activity was eluted with a 30-column volume
gradient from 50 to 500 mM KCl. The activity eluted between 190 and
330 mM KCl and was dialyzed against buffer A containing 50 mM KCl
and 0.02% Nonidet P-40 (Nonidet P-40) which was added to all buffers
from this stage on to increase protein stability. The active pool was
loaded on an 8-ml Mono Q, washed with 2 column volumes, and devel-
oped with a 10-column volume gradient 50–500 mM KCl. The Q/R
editing activity eluted both in the flow-through and between 50 and 280
mM KCl. Due to the presence of DRADA in the Mono Q flow-through,
the final two columns were run separately with either the Mono Q
flow-through or bound fraction, and these active pools were not com-
bined. The conductivity of the Mono Q flow-through and bound fraction
was adjusted to 500 mM KCl, and they were loaded separately onto a 5
ml poly(I)zpoly(C) (Pharmacia Biotech Inc.) column. The column was
washed with 2 column volumes and developed with an 8-column volume
gradient from 500 to 2500 mM KCl. The Q/R editing activity eluted from
both columns between 600 and 1800 mM KCl; the conductivity of the
active pools was adjusted to 250 mM KCl by dilution with buffer A
minus KCl and was loaded separately onto a 6-ml poly(G)zpoly(C) col-
umn which had been prepared as described previously (22). The column
was washed with 2 column volumes and developed with a 7-column
volume gradient between 250 and 1000 mM KCl. The Q/R editing
activity eluted between 370 and 500 mM KCl. Protein concentration was
determined by the Bradford method (34) with BSA as reference stand-
ard, except for the pure protein which was quantified on an SDS-
polyacrylamide gel with different amounts of BSA as reference
standard.
The DRADA extract used was from a previous purification prepared
in a similar manner as described above except that the DRADA activity
was in the flow-through of the Mono Q column, and all the Q/R editing
activity bound to the column. The DRADA activity from the Mono Q
flow-through was concentrated 3-fold by Centricon 30 (Amicon), and the
units used in experiments corresponded approximately to 100 fmol of
inosine/min as measured on dsRNA.
In Vitro Editing—DsRNA was transcribed and assayed for dsRNA
adenosine deaminase activity as described previously (22). The assay
was performed at 30 °C. An analysis of the GluR-B minigene B13 was
performed by primer extension assay with B-RT primer specific for the
Q/R site and the BHS-RT primer specific for hotspot 1. In the standard
assay, 10 fmol of in vitro transcribed RNA derived from minigene B13
was incubated with extract for 1–3 h at 30 °C. The reaction mixture was
then treated with proteinase K, phenol chloroform-extracted, and eth-
anol-precipitated. 10 fmol of the appropriate radioactive primer was
added and processed as described (10). The primer extension products
were quantified on a PhosphorImager 425 (Molecular Dynamics).
Sequence Analysis of Edited GluR-B Pre-mRNAs—To determine the
specificity of editing, reverse transcriptase-PCR amplification and sub-
sequent sequencing of RNAs incubated with either hRED1 (60% con-
version of adenosine to inosine per hour measured by primer extension
assay) or DRADA (100 fmol of inosine/min as measured on dsRNA) was
performed (10). After in vitro editing the RNAs were reverse-tran-
scribed (SuperscriptTM ll RT, Life Technologies, Inc.), and the specific
primers were KMH3 for the Q/R site and BFFK3 for the R/G site. The
cDNAs were then amplified by a two-step PCR protocol; in the first
amplification the primers were cis55 which is complementary to the
vector into which the GluR transcripts were cloned and PCRK3 which
primes at the 59-end of the RT primers. The PCR was performed under
standard conditions. In the second PCR, cis55 and MH50 were the
primers used to specifically amplify the Q/R site and cis55 and Bint2 the
primers for the R/G site. The PCR products were then gel-purified,
quantified, and approximately 60 ng was used in a sequencing reaction
on an Applied Biosystems 373A sequencer with dye terminators (Per-
kin-Elmer) according to the manufacturer’s instructions. MH36 was the
sequencing primer for minigene B13 and Bint1 for minigene pBgl.
Overexpression of Histidine-tag Fusion Protein and Antiserum Prep-
aration—The ESTs, L25485 and T70335 are 81.3 and 80.7% homolo-
gous to RED1. They were amplified from HeLa cDNA with the comple-
mentary PCR primers R1 and R2 which contained restriction sites at
their termini. The 575-base pair PCR product was subcloned into the
BamHI and HindIII sites in the polylinker of the histidine tag expres-
sion vector pTrcHisA (Invitrogen) and sequenced. Escherichia coli
strain BL-21 was transformed with pTrcH-EST1/2 and subsequently
induced at A600 5 0.6 with 1 mM isopropyl-b-D-thiogalactopyranoside for
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3 h at 37 °C. The overexpressed fusion protein was purified under
denaturing conditions on a nitrilotriacetic acid-Ni21 affinity column as
specified by the manufacturer (Qiagen). Aliquots from fractions of the
nitrilotriacetic acid-Ni21 affinity column were analyzed by electro-
phoresis on an SDS-polyacrylamide gel and detected with Anti-
XpressTm antibody 1:10,000 (Invitrogen). Approximately 100 mg of pure
recombinant protein was gel-purified and injected subcutaneously into
a New Zealand White rabbit which had first been bled to obtain pre-
immune serum. The antigen was emulsified with Specol adjuvant (Cen-
tral Veterinary Institute, Lelystad, The Netherlands). The rabbit was
boosted every 3 weeks with 50–100 mg of antigen, and blood was
collected approximately 10 days after each boosting.
Immunoblot Analysis—Proteins were separated on an 8% SDS-poly-
acrylamide gel, blotted on nitrocellulose, and detected with chemilumi-
nescence staining (ECL kit, Amersham) as described previously (25).
The DRADA antiserum was diluted 1:4000, and the hRED1 antiserum
was diluted either 1:1000 or 1:4000.
RESULTS
Purification of hRED1 That Edits the GluR-B Q/R Site—The
partial separation of a Q/R editing activity that is distinct from
DRADA has previously been reported (12, 27). Here, we dem-
onstrate that this editing activity is the human homolog of
RED1; hence, it will be referred to as hRED1. HeLa cell nuclear
extract was chosen as the source for purification since it con-
tains an editing activity analogous to that found in vivo in the
brain that can specifically deaminate the adenosine at the
GluR-B Q/R site. hRED1 was purified by chromatography over
seven columns (Table I); ion exchange was the principal
method used. Since the editing activity was capable of unspe-
cifically deaminating adenosines in long dsRNA, the purifica-
tion scheme chosen is very similar to the purification of
DRADA from calf thymus (22).
The purification of hRED1 was greater than 7000-fold from
14.7 g of protein of HeLa cell nuclear extract (Table I), the
equivalent of approximately 2 kg of packed HeLa cells. The
large amount of protein necessitated the running of the first
two columns twice. The presence of RNases made the accurate
measurement of Q/R editing activity in nuclear extract impos-
sible, and the units of activity are estimated from the Macro-
Prep High Q pool. Aliquots of column fractions were dialyzed
and assayed for both the presence of DRADA and hRED1
activity by primer extension (10) and for their ability to deami-
nate adenosine to inosine on extended dsRNA (22). The two
editing activities eluted with overlapping peaks from the first
four columns, but only hRED1 activity was pooled for further
purification. The activities could be separated on a Mono Q
column to which the HeLa DRADA activity does not bind. In
general, hRED1 binds to Mono Q, but in this particular puri-
fication the activity split with half binding and the other half
eluting in the flow-through. This was not the result of over-
loading the column since the protein did not bind when reap-
plied to a larger column. A similar problem had previously been
encountered during the purification of DRADA from calf thy-
mus (22). The hRED1 used in subsequent experiments was
derived from the fraction that bound to Mono Q and contained
no detectable DRADA activity.
A 30-fold purification of hRED1 was achieved by chromatog-
raphy on a poly(I)zpoly(C) column, and the enzyme was further
purified and concentrated on a poly(G)zpoly(C) column (Table
I). The activity profile of this column shows a peak of activity in
fractions 16–22 (Fig. 1A). This profile corresponds to Q/R edit-
ing analyzed by primer extension (Fig. 1B). The load fraction
was too dilute, and only a faint band corresponding to editing
activity is seen. No edited product was observed when the
hotspot 1 site, which is edited by DRADA, was analyzed by the
primer extension assay with these same column fractions (data
not shown). A band of approximately 90 kDa co-migrated with
Q/R editing activity when these fractions were electrophoresed
on a 7.5% SDS-polyacrylamide gel (Fig. 1C). This band is the
upper part of a doublet that could only be visualized by elec-
trophoresis on a long SDS-polyacrylamide gel and allowing the
45-kDa marker to migrate out of the gel. The lower band of the
doublet is present in the flow-through and in most fractions up
to fraction number 24 and does not migrate with activity,
neither does a smaller polypeptide of approximately 85 kDa
which is also present in the flow-through. Moreover, antibodies
generated to the deaminase domain of hRED1 specifically rec-
ognize only the upper band in the doublet (see below).
Substrate Specificity and Reaction Requirements of
hRED1—To confirm the specificity of hRED1, reverse tran-
scriptase-PCR was performed on the products of the editing
reaction and were then sequenced (see “Experimental Proce-
dures” for details). The trace data of the nucleotides adenosine
and guanosine surrounding the Q/R, hotspot 1, and R/G site are
depicted in Fig. 2, A and B (upon reverse transcription inosine
appears as guanosine). Partially purified DRADA was very
efficient at converting adenosine to guanosine at hotspot 1 in
intron 11 but only converted approximately 25% of the ad-
enosines at the Q/R site and 10% at position 14 (Fig. 2A). On
the other hand hRED1 was capable of converting all ad-
enosines at the Q/R site, approximately 20% at the 14 position
and none at hotspot 1. Both enzymes converted adenosines at
the R/G site (Fig. 2B), DRADA approximately 75% and the
90-kDa enzyme 80%. No other nucleotides were edited, as
detected by sequencing the PCR products (data not shown),
thereby confirming that hRED1 could specifically edit the Q/R
and R/G sites in vitro.
Pure hRED1 is not as stable as DRADA and is very sensitive
to freeze-thawing. Assays with the pure enzyme were per-
formed in the presence of 20% glycerol to help stabilize the
protein. Like DRADA it requires neither additional cofactors
nor ATP for its editing activity. The temperature and KCl
optimum of the enzyme were measured on extended dsRNA as
this has a more stable conformation than GluR-B pre-mRNA.
The editing activity has a temperature optimum between 35
and 37 °C but still retains 80% of its activity at 42 °C. The KCl
TABLE I
Purification of hRED1 from HeLa cell nuclear extract
Fraction Protein Activity Specific activity Purificationfactor Recovery
mg unitsa units/mg %
HeLa nuclear extract 14,670 87,349
Macroprep Q pool 5,610 210,800 38 1 100
Affi-Gel Blue pool 657 100,800 153 4 48
Hydroxyapatite pool 147 73,946 503 13 35
Mono S pool 51 53,280 1,036 28 25
Mono Q pool 33 41,158 1,262 34 19
Poly(I) z poly(C) pool 1 38,868 38,868 1,034 18
Poly(G) z poly(C) pool 0.1 33,823 281,858 7,501 16
a One unit 5 1% editing per min of the GluR-B pre-mRNA at the Q/R site.
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optimum is 100 mM, but no significant decrease in activity is
observed between 25 and 150 mM KCl (data not shown).
In competition experiments with 100 ng of poly(A), poly(U),
poly(C), and poly(G), poly(U) inhibited the hRED1 activity by
97% (Fig. 3). The other polynucleotides either stimulated the
enzyme [poly(A)] or inhibit only minimally by 5%. The affinity
for poly(U) is very high, and when hRED1 is applied to a
poly(U) column it is not possible to recover any activity from
the column by high salt elution, which maybe due to binding of
the enzyme irreversibly. This is in contrast to DRADA which is
only inhibited by poly(G) (22) and unaffected by the addition of
poly(U). The activity of DRADA is strongly inhibited by o-
phenanthroline which probably chelates a Zn21 ion that is
required at its active site (25). At 5 mM o-phenanthroline
DRADA is inhibited by 90% in comparison to the 30% inhibi-
tion of activity observed with hRED1 at the same o-phenan-
throline concentration (Fig. 3). This result suggests that if
there is an ion at the active site of hRED1, it is less accessible
than in DRADA. Both enzymes are very sensitive to N-ethyl-
maleimide (NEM), at 5 mM the activity of hRED1 is inhibited
on a 7.5% SDS-polyacrylamide gel, and proteins were visualized by
silver staining. Molecular masses of the size markers are indicated in
kilodaltons on the left. The arrow on the right points to a protein of
approximately 90 kDa.
FIG. 1. Chromatography of a 90-kDa enzyme with GluR-B
(Q/R) editing activity on a poly(G)zpoly(C) column. A, the activity
profile of the final poly(G)zpoly(C) column measuring the conversion of
adenosine to inosine by the primer extension assay. The units are
expressed as the percent conversion of adenosine to inosine per hour. B,
every other fraction of the poly(G)zpoly(C) column was analyzed for Q/R
editing by primer extension. The arrows indicate the position of P, the
primer, U, the unedited product, and E, the edited product. The first
lane shows the negative control without protein. Lanes 2 and 3 contain
the load fraction, 0.5 and 1 ml, respectively. The flow-through was
collected in 10 fractions, and 0.25 ml of it (f2–f10) as well as fractions
2–34 were assayed. C, SDS-polyacrylamide gel electrophoresis of
poly(G)zpoly(C) column fractions. Aliquots of 15 ml were electrophoresed
FIG. 2. Sequence analysis of GluR-B at Q/R, hotspot 1, and R/G
sites. GluR-B pre-mRNA B13 (encoding the Q/R and 160 hotspot 1
sites) and pBgl (encoding the R/G site) were incubated with either
DRADA or hRED1. The RNA was analyzed by reverse transcriptase-
PCR, and the products were sequenced, as described under “Experi-
mental Procedures.” A, the trace data of the sequence surrounding
GluR-B Q/R, 14, and hotspot (160). Only the traces of adenosine and
guanosine are shown. GluR-B was edited by both DRADA and hRED1;
an arrow marks the Q/R and 160 sites. The edited nucleotides are in
bold and underlined. B, the trace data of the sequence surrounding the
GluR-B R/G site, which is edited by both DRADA and hRED1. An arrow
indicates the edited nucleotides which are in bold and underlined.
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by 85%, whereas DRADA is inhibited by 95% (Fig. 3).
The 90-kDa Protein Is the Human Homolog of RED1—Two
ESTs, L25485 and T70335, listed in the data base have a high
homology to the deaminase domains of RED1 and DRADA (32).
A 575-base pair PCR fragment encoding both ESTs was fused
to a histidine tag; the resulting protein was overexpressed in E.
coli, and polyclonal antibodies were generated in a rabbit (see
“Experimental Procedures” for details). This antiserum recog-
nized the 90-kDa protein in fractions 16–20 of the
poly(G)zpoly(C) column (Fig. 4A). Therefore, we conclude that
we have purified the human homolog of RED1 because the
same band that co-eluted with editing activity was detected in
these fractions on the silver-stained SDS-polyacrylamide gel
(Fig. 1C).
The nucleotide sequence of hRED1 has a high homology to
RED1 from rat2 and contains two dsRBD. Polyclonal antibodies
directed against the first dsRBD of HeLa DRADA (25) recog-
nized both the HeLa and the calf thymus enzyme but not
hRED1 (Fig. 4B). The anti-hRED1 serum, raised against the
deaminase domain of hRED1 recognized hRED1 but not
DRADA (Fig. 4B). This result suggests that even though the
two adenosine deaminases contain similar dsRBDs and deami-
nase domains, they are sufficiently different to prevent cross-
reaction of the specific serum. The hRED1 antiserum inhibited
approximately 50% of the deaminase activity of hRED1 but did
not inhibit DRADA (data not shown). This is additional proof
that the purified 90-kDa enzyme is indeed hRED1 and not a
new member of the dsRNA adenosine deaminase family.
DISCUSSION
Ca21 permeability of the AMPA receptors is controlled by the
presence in their GluR-B subunit of an arginine residue at the
Q/R site that is generated by RNA editing of pre-mRNA (15,
16). There have been contradictory reports in the literature
concerning the enzyme(s) that mediate this editing event (12,
27, 29–32). It was reported that DRADA edited the hotspot 1
site in intron 11 but required additional cofactors to edit the
Q/R site (30, 31). Other investigators found that DRADA could
be partially separated from the Q/R editing activity (12, 27).
Melcher et al. (32) reported that a novel enzyme RED1 was
responsible for the editing of the Q/R site. Here, we confirm the
latter results by demonstrating that the Q/R site is edited in
vitro by a 90-kDa enzyme from HeLa cells that represent the
human homolog of RED1. The R/G site is edited to almost the
same extent by hRED1 and DRADA, whereas the hotspot 1 in
intron 11 is edited by DRADA only.
The 90-kDa homolog of RED1 was purified more than 7000-
fold from HeLa cell nuclear extract by ion exchange chroma-
tography. To ensure that the purified enzyme had the same
fidelity of editing in vitro as was observed in vivo (11, 18), PCR
products of the edited GluR-B RNA were sequenced directly so
that populations instead of individual clones could be analyzed.
A subset of the sequencing data is shown in Fig. 2. No nonspe-
cific editing was observed with either hRED1 or DRADA. It is
interesting to speculate why two similar enzymes are required
to edit adenosines at two different sites in GluR-B pre-mRNA.
The answer may lie in the different structural environment of
the adenosines that are edited (27). Double-stranded RNA
forms an A-type helix, and the amino group of the adenosine
that is deaminated lies in the poorly accessible major groove
(35). DRADA can deaminate the amino group of an adenosine
2 A. Gerber, M. A. O’Connell, and W. Keller, manuscript in
preparation.
FIG. 3. Inhibition of hRED1 and DRADA activity. Competition
experiments were performed with 100 ng of poly(A), poly(U), poly(C)
and poly(G); o-phenanthroline (OPA), and N-ethylmaleimide (NEM)
were tested for their inhibitory effects. Partially purified enzymes were
preincubated for 15 min before addition of RNA substrate. DRADA
(Mono Q flow-through) was assayed for adenosine deaminase activity
for 1 h at 37 °C (22), and hRED1 (Mono S peak fraction) was assayed for
editing of GluR-B pre-mRNA at the Q/R site for 1 h at 30 °C as described
under “Experimental Procedures.” The data shown here are results
from two independent experiments.
FIG. 4. Immunoblot of fractions from the final poly(G)zpoly(C)
column with anti-hRED1 serum. A, the same fractions (15 ml) from
the final poly(G)zpoly(C) as shown in Fig. 1C were electrophoresed on a
7.5% SDS-polyacrylamide gel and immunodetected with anti-hRED1
serum (1:1000). The molecular masses of the standards in kilodaltons
are on the left. An arrow on the right points to a 90-kDa protein. B,
immunoblot with anti-DRADA (1:3000) and anti-hRED1 (1:4000). Ali-
quots of 50 ml of pure calf thymus and partially purified HeLa DRADA
were precipitated with trichloroacetic acid (15%), and a 10-ml aliquot of
pure hRED1 was electrophoresed on an 8% SDS-polyacrylamide gel,
and proteins were detected by chemiluminescence.
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which is mismatched or in a bulge, such as at the R/G and
hotspot 1 sites (27) since a bulged adenosine widens the narrow
major groove to twice its normal width (36). In contrast, hRED1
is able to recognize and deaminate the adenosine at the Q/R
site which is present in a perfect duplex and is less accessible
(18). This appears to be the preferred substrate, since under
the same editing conditions hRED1 can edit the Q/R site to
100% but edits the R/G site to only 80% (Fig. 2), suggesting that
the adenosine at the R/G site is not in as favorable an
environment.
There are many similarities between DRADA and hRED1.
The purification scheme used for the purification of hRED1 is
comparable with that of DRADA (22), which reflects their sim-
ilarity in amino acid composition and the capacity of both
enzymes to bind dsRNA. Both proteins perform the same en-
zymatic reaction in the absence of additional cofactors and are
capable of deaminating up to 50% of the adenosines present in
extended dsRNA, and in particular, they both edit the adeno-
sine at the R/G site in GluR-B pre-mRNA. Even though editing
of GluR-B pre-mRNA occurs in the brain, the enzymes respon-
sible for this site-specific editing are present and active in
HeLa cells suggesting the existence of additional RNA sub-
strates for these enzymes in other cell types.
There is evidence that the two enzymes have differences in
their active site which may underly their ability to deaminate
adenosines in different editing sites. Both enzymes have oppo-
site behaviors in competition experiments with poly(U) and
poly(G); poly(U) completely inhibits the activity of hRED1,
whereas poly(G) inhibits DRADA (Fig. 3). Differences were also
observed when o-phenanthroline was added to the editing re-
action; hRED1 was less sensitive to the inhibitor than DRADA
(Fig. 3). This suggests that if there is a Zn21 ion at the active
site of hRED1, its environment is different to that in DRADA.
Antibodies directed against the deaminase domain of hRED1
only recognize hRED1 (Fig. 4B) and are able to inhibit its
activity but not that of DRADA. Taken together, these results
suggest that even though the two enzymes share a high se-
quence homology (32),2 the property of their active sites is
different.
Apolipoprotein B (apoB) mRNA is edited by the deamination
of a specific cytidine to a uridine, generating a new transla-
tional stop codon (2, 3). This editing is mediated by a cytidine
deaminase termed APOBEC-1, which is the catalytic subunit of
a multi-subunit editing complex (37). Even though the editing
of the apoB transcript occurs by a very different enzymatic
mechanism, APOBEC-1, DRADA and RED1 resemble each
other in their active sites, as the amino acids thought to coor-
dinate a Zn21 ion are conserved (24, 25, 32). Recently, the
mRNA of neurofibromatosis type 1 (NF1) was also found to be
edited by cytidine deamination (38). This editing requires a
tripartite motif that is highly homologous to the apoB mooring
sequence but is not influenced by addition of APOBEC-1, sug-
gesting that a different catalytic subunit may be involved in
this editing reaction.
RNA editing enzymes involved in specific deamination, the
cytidine deaminases and the dsRNA adenosine deaminases,
seem to belong to families of proteins whose members have
different or overlapping substrate specificities. Because these
enzymes are related in their primary amino acid sequence,
their enzymatic mechanisms as well as their function are prob-
ably very similar. Thus, it is surprising that there exist so
many different editing deaminases. A possible explanation
could be that RNA editing has to be regulated. This can be
achieved either at the RNA substrate level by the binding of
auxiliary factors or by controlling the expression of RNA edit-
ing enzymes that differ in their specificity of RNA recognition.
The degree of editing of a specific site can vary in different
tissues and during development. Perhaps it is easier and more
direct to regulate the expression of specific editing enzymes
than to control the potential of sites in the RNA to be edited by
different RNA binding proteins.
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